On March 22, 2024, HOOKIPA Pharma Inc. reported its financial results for the fourth quarter and full year of 2023. The announcement highlighted several key developments, including promising preliminary Phase 2 data for HB-200 in treating HPV16+ head and neck cancers, progress on the HB-700 program for KRAS mutated cancers, and advancements in infectious disease programs in partnership with Gilead. HOOKIPA also announced a strong cash position at the end of 2023, with $117.5 million, bolstered by capital raises and collaboration-based milestones. The company is preparing for pivotal trials and IND submissions in 2024. Additionally, HOOKIPA will regain full control of the HB-700 program's intellectual property and rights from Roche as of April 25, 2024. Financially, the company reported an increase in revenue for the year, primarily due to the recognition of upfront and milestone payments from collaborations. However, the company also faced increased research and development expenses and an impairment expense related to the discontinuation of a GMP manufacturing facility project. The net loss for the year increased compared to 2022, reflecting these higher expenses.

On March 22, 2024, HOOKIPA Pharma Inc. reported its financial results for the fourth quarter and full year of 2023. The announcement highlighted several key developments, including promising preliminary Phase 2 data for HB-200 in treating HPV16+ head and neck cancers, progress on the HB-700 program for KRAS mutated cancers, and advancements in infectious disease programs in partnership with Gilead. HOOKIPA also announced a strong cash position at the end of 2023, with $117.5 million, bolstered by capital raises and collaboration-based milestones. The company is preparing for pivotal trials and IND submissions in 2024. Additionally, HOOKIPA will regain full control of the HB-700 program's intellectual property and rights from Roche as of April 25, 2024. Financially, the company reported an increase in revenue for the year, primarily due to the recognition of upfront and milestone payments from collaborations. However, the company also faced increased research and development expenses and an impairment expense related to the discontinuation of a GMP manufacturing facility project. The net loss for the year increased compared to 2022, reflecting these higher expenses.